ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1070

Phenotypic Characterization of Peripheral Basophil Perturbations in the Antiphospholipid Syndrome

Benjamin Chaigne1, Veronique Le Guern2, Tali-Anne Szwebel1, Romain Paule2, Claire Le Jeunne3, Nathalie Costedoat-Chalumeau4 and Luc Mouthon5, 1Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes Rares d’Ile de France, hôpital Cochin, DHU Authors, Assistance Publique-Hôpitaux de Paris, Paris, France, 2Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, Paris, France, 3Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, 4Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, 5Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Antiphospholipid syndrome and innate immunity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Innate Immunity and Rheumatic Disease Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

The antiphospholipid syndrome (APS) is an autoimmune condition characterized by thrombosis, pregnancy complications and the presence of antiphospholipid antibodies. Basophils, which have long been associated with allergy and parasitic infections, are known to be activated and able to enhance the production of autoantibodies in autoimmune diseases, particularly in systemic lupus erythematosus (SLE). Herein we investigated the role of basophils in APS.

Methods:

Peripheral basophils of patients with primary APS, SLE-associated APS (SLE-APS), and healthy controls (HC) were analyzed using flow cytometry.

Results: Forty-three consecutive patients with APS, including 10 patients with SLE-APS, and 20 HC were recruited. None of the patients was treated with corticosteroids or immunosuppressants. Thirty-five (81.4%) patients had lupus anticoagulant, 33 (76.7%) had anti-cardiolipin antibodies, and 24 (55.8%) had anti-ß2 glycoprotein I. Twenty (46.5%) patients had obstetric APS, 20 (46.5%) patients experienced arterial thrombosis and 19 (44.2%) patients experienced venous thrombosis. Six patients (14%) had a catastrophic APS (CAPS). Basophil activation markers revealed a decreased proportion of CD193+ basophils in patients with APS vs HC (63.0% [27.3 – 85.0] vs 90.4% [74.1 – 97.1]; p < 0.05) and an increased mean fluorescence intensity (MFI) of CD69 within basophils in patients with APS vs HC (839 [436 – 1434] vs 318 [103 – 755]; p < 0.05). Basophils functional markers revealed a decreased proportion of CD62L+ basophils in APS vs HC (99.0% [95.6 – 100] vs 100% [99.6 – 100]; p < 0.05), and an increased proportion of HLA-DR+ basophils in APS vs HC (32.3% [16.8 – 77.2] vs 10.0% [3.4 – 21.7]; p < 0.05). There was no difference between patients with APS and patients with SLE-APS, or patients with CAPS. When compared to patients without obstetric APS, patients with obstetric APS (46.5%) had a decreased proportion of CD196+ basophils (25.5% [11.3 – 32.5] vs 31.9% [25.8 – 66.3]; p < 0.05), an increased proportion of CD63+basophils (34.8% [0.25 – 53.3] vs 7.4% [0 – 37.9]; p < 0.05), and an increased proportion of HLA-DR+ basophils (49.0% [23.4 – 79.6] vs 20.8% [8.7 – 70.8]; p < 0.05). Lastly, the proportion of CD154+ basophils was higher in patients who experienced miscarriages than those who did not (47.6% [38.2 – 56.1] vs 19.7%[5.1 – 35.8]; p < 0.01) and MFI of basophil CD62L was higher in patients who experienced fetal death in utero than those who did not (11823 [9862 – 15546] vs 7978 [4628 – 10160]; p < 0.05).

Conclusion:

Main phenotypic characteristics of basophils in APS are an increased expression of CD69 marker, a decreased expression of CD193 marker, and an increased expression of HLA-DR marker suggesting a role for basophils. Patients with obstetric APS differed from other APS patients by a skewed distribution of CD196+, CD63+ and HLA-DR+ basophils.


Disclosure: B. Chaigne, None; V. Le Guern, None; T. A. Szwebel, None; R. Paule, None; C. Le Jeunne, None; N. Costedoat-Chalumeau, None; L. Mouthon, None.

To cite this abstract in AMA style:

Chaigne B, Le Guern V, Szwebel TA, Paule R, Le Jeunne C, Costedoat-Chalumeau N, Mouthon L. Phenotypic Characterization of Peripheral Basophil Perturbations in the Antiphospholipid Syndrome [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/phenotypic-characterization-of-peripheral-basophil-perturbations-in-the-antiphospholipid-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/phenotypic-characterization-of-peripheral-basophil-perturbations-in-the-antiphospholipid-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology